Register Login

Cocrystal Pharma Inc. (COCP)

(10% Negative) Cocrystal Pharma, Inc. (COCP) Announces Delay in apply Trials for a larger Phase II award Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations

Full text
Register to leave comments
  • News bot Oct. 27, 2025, 6:06 p.m.

    📋 Cocrystal Pharma, Inc. (COCP) - Clinical Trial Update

    Filing Date: 2025-10-27

    Accepted: 2025-10-27 14:03:56

    Event Type: Clinical Trial Update

    Event Details:

    Cocrystal Pharma Inc. (COCP) Announces Clinical Trial Update Cocrystal Pharma Inc. (COCP) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: apply, technology
    • Diseases/Conditions: a larger Phase II award
    • Clinical Stage: Phase I, Phase II
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Regulatory Process
    • Collaboration: National Institute of Allergy
    • Updated Timeline: October 27, 2025
      • targeting potent, broad-spectrum drugs toward the path of clinical development,” said Sam Lee, PhD, Cocrystal President and co-CEO. “We appreciate the funding and confidence from NIH, which further validates our structure-based drug discovery platform technology in developing new antiviral treatments.” The NIH/NIAID Phase I award is designed to assess the scientific, technical and commercial potential of early-stage programs. Successful completion of Phase I may qualify the recipient eligible to apply for a larger Phase II award, which provides additional substantial funding to continue development. “We have prioritized the pursuit of government and military funding to advance our antiviral pipeline while building shareholder value,” said James Martin, Cocrystal CFO and co-CEO. “This is an important milestone as we continue our work to secure additional non-dilutive capital.” The research is supported by the National Institute of Allergy and Infectious Diseases of the NIH under award number 75N9302
      • anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, the risks and uncertainties arising from the U.S. government shutdown in October 2025
      • targeting which may result in variants that are resistant to a product candidate we develop and our liquidity needs. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2024

    🔬 Clinical Development Pipeline (Cocrystal Pharma, Inc.):

    Product Type Development Stage Therapeutic Area Source
    Snow Mountain Virus OTHER Phase PHASE1 Norovirus ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Norovirus ClinicalTrials.gov
    CDI-988 DRUG Phase PHASE1 Norovirus ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Cocrystal Pharma Inc.
    • CIK: 0001412486
    • Ticker Symbol: COCP
    • Period End Date: 2025-10-27
    • Document Type: 8-K

Search

News categories